FDA Warns Sanofi Over Taxotere Marketing Claims

Law360, New York (May 13, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has warned Sanofi-Aventis over including what regulators have said are misleading statements in marketing materials for the breast cancer treatment Taxotere that tout the treatment over paclitaxel, which is sold by Bristol-Myers Squibb Co. under the brand name Taxol.

In a letter released Wednesday, the FDA chastised the French drugmaker for disseminating a reprint of an article from the Journal of Clinical Oncology describing a study that regulators say overstates the effectiveness of the drug.

The article claimed Taxotere was...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.